| Thursday, September 25 | |
|---|---|
| 17:30-18:00 | Evidence for treatment of chronic GvHD using ECP – A future backbone for GvHD Therapy Industry-supported Meet the Expert Session |
| Friday, September 26 | |
|---|---|
| 08:15-08:30 | Good Morning Coffee |
| 08:30-08:45 | Welcome Note Congress Co-Chairs |
| 08:45-10:15 | Session 1: CAR-T Cell Therapy |
| Controversy: Is there a future for CAR-T cell therapy in T-All? | |
| Moderator: Nicolaus Kröger, Germany | |
| 08:45-09:00 | Yes: He Huang, China |
| 09:00-09:15 | No: Sebastian Giebel, Poland |
| Controversy: Is survival prolonged if we used CAR-T in second line rather than third-line treatment? | |
| Moderator: Arnon Nagler, Israel | |
| 09:15-09:30 | Yes: Anna Sureda, Spain |
| 09:30-09:45 | No: Roni Shouval, USA |
| 09:45-10:15 | Panel discussion: All session faculty |
| 10:15-10:45 | Coffee Break, Poster Viewing and Visit Exhibition |
| 10:45-12:15 | Session 2: Stem Cell Transplantation in AML |
| Controversy: Shall we include venetoclax in the induction chemotherapy and/or conditioning regimen before the transplant? | |
| Moderator: Avichai Shimoni, Israel | |
| 10:45-11:00 | Yes: Thomas Schroeder, Germany |
| 11:00-11:15 | No: Jurjen Versluis, Netherlands |
| Controversy: Should we transplant TP53 multi-hit AML or MDS? | |
| Moderator: Mutlu Arat, Turkey | |
| 11:15-11:30 | Yes: Coleman Lindsley, USA |
| 11:30-11:45 | No: Avichai Shimoni, Israel |
| 11:45-12:15 | Panel discussion: All session faculty |
| 12:15-13:15 | Session 3: Post-Transplant Lymphoproliferative Disorders |
| How to treat PTLD post allograft refractory to anti CD20 therapy? | |
| Chair: Rafael de la Cámara, Spain | |
| 12:15-12:30 | By EBV specific T cells: Guenther Koehne, USA |
| 12:30-12:45 | By CAR T cells: Marcos de Lima, USA |
| 12:45-13:00 | By chemotherapy and DLI: Rafael de la Cámara, Spain |
| 13:00-13:15 | Discussion |
| 13:15-14:00 | Lunch Break, Poster Viewing and Visit Exhibition |
| 14:00-15:00 | Controversy in FLT3-AML: Can MRD guide the way to clinical decisions along the patient pathway? Industry-supported Lunch Symposium |
| 15:00-15:45 | Session 4: Immunotherapy in AML |
| Controversy: Is there a future for immunotherapy in AML outside allogeneic SCT? | |
| Moderator: Charles Craddock, UK | |
| 15:00-15:15 | Yes: Fabio Ciceri, Italy |
| 15:15-15:30 | No: Alexandros Spyridonidis, Greece |
| 15:30-15:45 | Discussion |
| 15:45-16:15 | Coffee Break, Poster Viewing and Visit Exhibition |
| 16:15-17:45 | Session 5: Myelodysplastic Neoplasms (MDS) |
| Controversy: Does MRD before allo impact the outcome for MDS? | |
| Moderator: Fernando Barroso Duarte, Brazil | |
| 16:15-16:30 | Yes: Carmelo Gurnari, Italy |
| 16:30-16:45 | No: Arjan van de Loosdrecht, Netherlands |
| Controversy: Is venetoclax the new partner for 5-Aza in MDS? | |
| Moderator: Arjan van de Loosdrecht, Netherlands | |
| 16:45-17:00 | Yes: Valeria Santini, Italy |
| 17:00-17:15 | No: Moshe Mittelman, Israel |
| 17:15-17:45 | Panel discussion: All session faculty |
| Saturday, September 27 | |
|---|---|
| 08:30-09:30 | Session 6: A CME Symposium on Multiple Myeloma |
| Controversy: Are we ready for CAR-T in first-line therapy for MM? | |
| Moderator: Nico Gagelmann, Germany | |
| 08:30-08:40 | Yes: Jan Krönke, Germany |
| 08:45-08:50 | No: Suzanne Lentzsch, USA |
| Controversy: BCMA targeted therapy: should we use CAR-Ts first in RRMM? | |
| Moderator: Suzanne Lentzsch, USA | |
| 08:50-09:00 | Yes: Ralph Wäsch, Germany |
| 09:00-09:10 | No: Cyrus Khandanpour, Germany |
| 09:10-09:30 | Panel discussion: All session faculty |
| 09:30-10:00 | Coffee Break, Poster Viewing and Visit Exhibition |
| 10:00-11:00 | Should extended CMV prophylaxis for seropositive patients become the new standard in clinical practice? Industry-supported Symposium |
| 11:00-12:20 | Session 7: GvHD Prophylaxis |
| Controversy: Is PTCy or ATG-based prophylaxis the better haplo approach in AML? | |
| Moderator: Nicolaus Kröger, Germany | |
| 11:00-11:15 | ATG/ATLG: Xiaojun Huang, China |
| 11:15-11:30 | PTCy: Leo Luznik, USA |
| Controversy: Does HLA matter in HSCT with PTCy? | |
| Moderator: Arnon Nagler, Israel | |
| 11:30-11:45 | Yes: Katharina Fleischhauer, Germany |
| 11:45-12:00 | No: Leslie Kean, USA |
| 12:00-12:20 | Panel discussion: All session faculty |
| 12:20-13:00 | Lunch Break, Poster Viewing and Visit Exhibition |
| 13:00-14:30 | Redefining what’s possible in GvHD care: How can pathophysiology guide treatment and its intensification? Industry-supported Lunch Symposium |
| 14:30-15:50 | Session 8: Spleen in MPN & Cord for GVL |
| Controversy: Splenectomy vs spleen irradiation in JAKi resistant MPN patients prior to alloSCT | |
| Moderator: Donal McLornan, UK | |
| 14:30-14:45 | Pro splenectomy: Nicola Polverelli, Italy |
| 14:45-15:00 | Pro spleen irradiation: Nico Gagelmann, Germany |
| 15:00-15:10 | Discussion |
| Controversy: Does cord blood provide a stronger GVL effect? |
|
| Moderator: Miguel-Angel Perales, USA | |
| 15:10-15:25 | Yes: Robert Wynn, UK |
| 15:25-15:40 | No, stronger GVL with CB: Arnon Nagler, Israel |
| 15:40-15:50 | Discussion |
| 15:50-16:05 | Coffee Break, Poster Viewing and Visit Exhibition |
| 16:05-17:25 | Session 9: Prevention of GvHD |
| Controversy: Can modulation of microbiome by diet prevent or treat GvHD? | |
| Moderator: Ernst Holler, Germany | |
| 16:05-16:20 | Yes: Marcel van den Brink, USA |
| 16:20-16:35 | No: Hendrik Poeck, Germany |
| Controversy: Is fecal transplant the future treatment of SR-GvHD? | |
| Moderator: Marcel van den Brink, USA | |
| 16:35-16:50 | Yes: Ernst Holler, Germany |
| 16:50-17:05 | No: Pavan Reddy, USA |
| 17:05-17:25 | Panel discussion: All session faculty |
| 17:25-18:45 | Session 10: GvHD Treatment |
| Controversy: Is there a role for combining JAKi with other agents in acute and chronic GvHD? | |
| Moderator: Francesca Bonifazi, Italy | |
| 17:25-17:40 | Yes: Hildegard Greinix, Austria |
| 17:40-17:55 | No: Olaf Penack, Germany |
| Controversy: Are MAGIC criteria and biomarker the standard for classifying and treating acute GvHD? |
|
| Moderator: Ibrahim Yakoub-Agha, France | |
| 17:55-18:10 | Yes: James Ferrara, USA |
| 18:10-18:25 | No: Amin Alousi, USA |
| 18:25-18:45 | Panel discussion: All session faculty |
| 18:45 | Poster Walk and Awards Session (Poster Area) |
| Sunday, September 28 | |
|---|---|
| 09:00-10:30 | Session 11: Future of Trials and GvHD |
| Controversy: Can modern technology (e.g. AI) of large registries replace projective phase III studies? |
|
| Moderator: Nicolaus Kröger, Germany | |
| 09:00-09:15 | Yes: Marcelo Pasquini, USA |
| 09:15-09:30 | No: Charles Craddock, UK |
| 09:30-09:45 | Discussion |
| Controversy: Can we expect CAR-T cells to treat GvHD? |
|
| Moderator: Marcelo Pasquini, USA | |
| 09:45-10:00 | Yes: Matteo Doglio, Italy |
| 10:00-10:15 | No: Bruce Blazar, USA |
| 10:15-10:30 | Discussion |
| 10:30-11:00 | Coffee Break |
| 11:00-12:30 | Session 12: Autoimmune Diseases and Follicular Lymphoma |
| Controversy: CAR-T vs BITE in autoimmune disease |
|
| Moderator: Raffaella Greco, Italy | |
| 11:00-11:15 | Pro CAR: Dimitrios Mougiakakos, Germany |
| 11:15-11:30 | Pro BITE: Tobias Alexander, Germany |
| Controversy: CAR-T vs BITE in advanced follicular lymphoma |
|
| Moderator: Valentín Ortíz-Maldonado, Spain | |
| 11:30-11:45 | Pro CAR: Wolfgang Bethge, Germany |
| 11:45-12:00 | Pro BITE: Anna Sureda, Spain |
| 12:00-12:30 | Panel discussion: All session faculty |
| 12:30 | Closing Remarks Congress Co-Chairs |
